BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor

(TheNewswire)

VANCOUVER, British Columbia, November 25, 2025 – TheNewswire - BetterLifePharma Inc. (“BetterLife” or the “Compa ny”) ( CSE:BETR / OTCQB:BETRF / FRA: NPAU ) ,an emerging biotech company, focused on development of BETR-001, itsproprietary non-hallucinogenic derivative of LSD. BetterLife ispleased to announce Daniel Carcillo will join the Company as CorporateAdvisor to advance BetterLife’s BETR-001 development with focus onTraumatic Brain Injury (“TBI”), cluster headache and migraine.

Mr. Carcillo is a Canadian formerprofessional hockey left winger who won two Stanley Cups as a memberof the Chicago Blackhawks of the National Hockey League (“NHL”).He was forced to retire at the age of 30 due to Post ConcussionSyndrome after seven concussions. After retiring from the NHL in 2015,Mr. Carcillo created a non-profit organization that assists formerNHL-players suffering from post-concussion syndrome and mental healthissues. A well-known speaker and advocate onbehalf of TBI survivors and people dealing with mental healthchallenges, Mr. Carcillo was the founder and CEO of Wesana Health, alife sciences company that leverages psilocybin-based medicine totreat traumatic brain injuries.

Mr. Carcillo stated, “Joining BetterLife feels likethe natural next step in my mission to help concussion survivorsbecause we are advancing a medicine that carries the promise ofpsychedelic healing without the regulatory barriers and with all theserotonergic benefits people desperately need. I have lived the impactof brain trauma and I know how powerful these breakthroughs can be.This is about giving athletes veterans and anyone living with theinvisible weight of concussion a real chance to heal and get theirlife back."

Dr. Ahmad Doroudian, CEO of BetterLife, commented,“We are very excited to have Mr. Carcillo joining our advisorygroup. His first hand experience with TBI and his passion to advancethe development of  medicines and treatments for those injuries willprovide us with invaluable guidance. We look forward to working withDaniel to advance the development BETR-001.”

About BetterLife Pharma

BetterLife Pharma Inc.is an emerging biotechnology company primarily focused on developingand commercializing BETR-001 to treat various neurological disorders.BETR-001, which is in preclinical and IND-enabling studies, is anon-hallucinogenic and non-controlled LSD derivative in developmentand it is unique in that it is unregulated and therefore can beself-administered. BetterLife’s synthesis patent for BETR-001eliminates regulatory hurdles and its pending patent, for compositionand method of use, covers treatment of various neurological disorders,until around 2042.

BetterLife also owns a drug candidate for the treatmentof viral infections and is in the process of seeking strategicalternatives for further development.

For further information, please visit BetterLifePharma .

Contact

Ahmad Doroudian, Chief Executive Officer

Email: Ahmad.Doroudian@blifepharma.com

Phone: 1-604-221-0595

Cautionary Note RegardingForward-Looking Statements

No securities exchange has reviewed nor acceptsresponsibility for the adequacy or accuracy of the content of thisnews release. This news release contains forward-looking statementsrelating to product development, licensing, commercialization andregulatory compliance issues and other statements that are nothistorical facts. Forward-looking statements are often identified byterms such as “will”, “may”, “should”, “anticipate”,“expects” and similar expressions. All statements other thanstatements of historical fact, included in this release areforward-looking statements that involve risks and uncertainties. Therecan be no assurance that such statements will prove to be accurate andactual results and future events could differ materially from thoseanticipated in such statements. Important factors that could causeactual results to differ materially from the Company’s expectationsinclude the failure to satisfy the conditions of the relevantsecurities exchange(s) and other risks detailed from time to time inthe filings made by the Company with securities regulations. Thereader is cautioned that assumptions used in the preparation of anyforward-looking information may prove to be incorrect. Events orcircumstances may cause actual results to differ materially from thosepredicted, as a result of numerous known and unknown risks,uncertainties, and other factors, many of which are beyond the controlof the Company. The reader is cautioned not to place undue reliance onany forward-looking information. Such information, although consideredreasonable by management at the time of preparation, may prove to beincorrect and actual results may differ materially from thoseanticipated. Forward-looking statements contained in this news releaseare expressly qualified by this cautionary statement. Theforward-looking statements contained in this news release are made asof the date of this news release and the Company will update or revisepublicly any of the included forward-looking statements as expresslyrequired by applicable law.

Copyright (c) 2025 TheNewswire - All rights reserved.